Médecine

Paramédical

Autres domaines


S'abonner

In vitro fertilization and preimplantation genetic diagnosis outcomes in mosaic Turner's Syndrome: A retrospective cohort study from a single referral center experience - 13/05/22

Doi : 10.1016/j.jogoh.2022.102405 
Ferruh Acet 1, , Gulnaz Sahin 2, Abdullah Ali Osman Uçar 3, Volkan Emirdar 4, Emin Karaca 5, Burak Durmaz 6, Ege Nazan Tavmergen Goker 7, Erol Tavmergen 8
1 Department of IVF Research and Training Center, Ege University Faculty of Medicine, Izmir, Turkey 
2 Department of IVF Research and Training Center, Ege University Faculty of Medicine, Izmir, Turkey 
3 Department of IVF Research and Training Center, Ege University Faculty of Medicine, Izmir, Turkey 
4 Department of Obstetrics and Gynecology, Izmir Economy University, Medical Park Hospital Izmir, Turkey 
5 Ege University, Faculty of Medicine, Department of Genetic, Ege University Faculty of Medicine, Izmir, Turkey 
6 Department of Genetic Ege University Faculty of Medicine, Izmir, Turkey 
7 Department of IVF Research and Training Center and Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Izmir, Turkey. 
8 Department of IVF Research and Training Center and Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Izmir, Turkey 

Corresponding author.
Sous presse. Manuscrit accepté. Disponible en ligne depuis le Friday 13 May 2022

Edited by Pr. Herve Fernandez

Abstract

Background

: Patients with mosaic Turner syndrome who have normal phenotype and pubertal development may be diagnosed based on karyotype examination which is performed due to recurrent abortion or recurrent implantation failure; but according to the literature review, reproductive and obstetric consequences of these cases are based on case reports. There are contradictory publications on this subject recommending pre-implantation genetic testing (PGT) may be a solution to reduce the high risk for the fetus and perform normal embryo transfer.

Aim

: In this study, our aim was to evaluate the results of in vitro fertilization and preimplantation genetic diagnosis in patients with low-grade and high-grade mosaic Turner syndrome.

Methods

: We collected data of patients between 2012 and 2018 from a single center retrospectively. The study analyzed 36 mosaic Turner syndrome patients, of whom, 10 patients were evaluated as high, 26 patients were evaluated as low-grade mosaic pattern for Turner syndrome.

Results

: Mean age (35,46±0,87 vs. 36,2±1,85) body mass index (25,26±0,74 vs. 30,8±0,63) baseline follicle stimulating hormone (5,73±0,74 vs. 6,70±1,17) basal luteinizing hormone (4,78±0,43 vs. 4,92±0,99) were similar between two groups. In the high-grade mosaic Turner Syndrome patients, duration of stimulation (7,60±0,16 vs. 8,0±0,28, p<0,001), total gonadotrophin dose (1540,0±165,12 vs. 2046,15± 111,47, p<0,001) and the number of normal karyotype embryos was statistically significantly higher (1,58±0,17 vs. 2,00±0,55, p<0,001). The Pregnancy rates in the low-grade and high-grade mosaic Turner syndrome patients’ cycles were 30,8% versus 30 %, (p = 0.76) respectively. IVF results were also evaluated by the presence of triploidy were accompanying Turner syndrome or not. In the presence of one or 2 X chromosomes, none of the included in the study could achieve live birth. The most common abnormality in the embryos was monosomy and trisomy of the chromosome13. In 30% of the cases, there were 2 or 3 abnormalities present together. In embryos with 2 abnormal chromosomes, the most common 2 abnormalities were monosomy 13 and trisomy 21, while trisomy 13, trisomy X and monosomy 18 were found in 3 or more abnormalities, respectively.

Conclusion

: In vitro fertilization and Preimplantation genetic diagnose should be considered in the infertility treatment of the patient with mosaic Turner Syndrome.

Le texte complet de cet article est disponible en PDF.

Keywords : IVF, PGD, Turner's syndrome


Plan


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.